0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Successful Treatment of Ulcerative and Diabeticorum Necrobiosis Lipoidica With Intravenous Immunoglobulin in a Patient With Common Variable Immunodeficiency FREE

Neda Barouti, MD1; Amy Qian Cao, H BSc1,2; Donato Ferrara, MD1; Christa Prins, MD1
[+] Author Affiliations
1Department of Medical Specialties–Dermatology, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland
2Queen’s University School of Medicine, Kingston, Ontario, Canada
JAMA Dermatol. 2013;149(7):879-881. doi:10.1001/jamadermatol.2013.4133.
Text Size: A A A
Published online

Necrobiosis lipoidica (NL) is an idiopathic inflammatory skin disorder that rarely resolves spontaneously, and ulceration is a major complication. Although NL occurs in less than 1% of patients with diabetes mellitus, 75% of NL cases are associated with diabetes.1

Common variable immunodeficiency (CVID) is the most frequent symptomatic primary immunodeficiency encountered in adults: incidence is estimated at between 1 in 10 000 and 1 in 50 000. Because of the heterogeneity of this disorder, no targeted therapy has been defined except intravenous immunoglobulin (IVIG).2 Herein, we describe a patient with diabetes who experienced a successful combined treatment of NL ulcers and CVID with IVIG.

REPORT OF A CASE

A 63-year-old white woman with diabetes was referred to us with a 7-year history of ulcerating and very painful NL lesions on her shins, which had gradually enlarged during this period. The patient was a smoker and had a history of well-controlled type 2 insulin-treated diabetes mellitus (hemoglobin A1c proportion, 6.1%) with no additional diabetic complication. Physical examination revealed atrophic, yellow-brown, telangiectatic plaques affecting her lower legs. The lesions had large, deep, and crusting ulcerations (Figure 1). Cutaneous biopsy findings were compatible with NL, and direct immunofluorescence findings were negative. The patient had previously received treatments with topical corticosteroid, topical tacrolimus, hydroxychloroquine, psoralen plus UV-A, and pentoxifylline without any significant clinical response. Owing to recurring ear, nose, and throat infections, CVID was suspected. Immunologic tests revealed a poor response to vaccines (pneumococcus and diphtheria) and reduced serum immunoglobulin concentrations (IgG, IgM, and IgA at 77, 23, and 40 mg/dL, respectively). No secondary cause of hypogammaglobulinemia was observed (no history of immunosuppressive therapy, digestive symptoms of inflammatory disease, nor evidence for neoplasia by thoraco-abdominal computed tomographic scan and flow cytometry).

Place holder to copy figure label and caption
Figure 1.
Clinical Images of Affected Areas Before Treatment

Lower pretibial right (A) and left (B) legs before intravenous immunoglobulin therapy showing large and ulcerative plaques of necrobiosis lipoidica.

Graphic Jump Location

The patient was subsequently treated with IVIG, 0.4g/kg/d, for 5 consecutive days for her newly diagnosed CVID, while local application of paraffin gauze dressing (Jelonet; Smith & Nephew) was maintained. Surprisingly, 3 weeks after this single cycle, all ulcerations had healed (Figure 2), and complete resolution of pain was reported. The immunoglobulin levels remained stable 3 months after IVIG treatment, and no further ulcerations were detected during a 2-year follow-up, and so the patient did not require additional therapy.

Place holder to copy figure label and caption
Figure 2.
Clinical Image of Affected Areas After Treatment

Lower pretibial aspect of the legs after Intravenous Immunoglobulin therapy showing substantial healing.

Graphic Jump Location

DISCUSSION

In our case, no significant success was observed in reduction of NL ulcers after administration of currently accepted treatments, the efficiency of which was known to be limited. Interestingly, treatment of the patient’s CVID with IVIG appeared to heal the ulcers within 3 weeks. As the IVIG treatment showed a similar dramatic ulcer reduction within 2 weeks in a previous case3 (where no investigation of associated hypogammaglobulinemia was performed), the immunologic aspect of NL appears of major importance in these patients. Because of its strong association with diabetes, NL has been postulated to arise due to microangiopathic vascular changes. Therefore, NL might be due to immunologically mediated vascular changes.4,5 In this context, measures of serum immunoglobulin levels and direct immunofluorescent histologic study might be recommended in NL.

Our findings suggest that IVIG can be a successful option in the treatment of NL, particularly in patients with CVID, while a broader approach in NL without underlying CVID requires further investigations.

ARTICLE INFORMATION

Corresponding Author: Neda Barouti, MD, Rue Gabrielle-Perret-Gentil 4, 1205 Genève, Switzerland (neda.barouti@hcuge.ch).

Conflict of Interests Disclosures: None reported.

Funding/Support: This study was supported by the University Hospitals of Geneva, Geneva, Switzerland.

Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.

REFERENCES

Ngo  B, Wigington  G, Hayes  K,  et al.  Skin blood flow in necrobiosis lipoidica diabeticorum. Int J Dermatol. 2008;47(4):354-358.
PubMed   |  Link to Article
Salzer  U, Warnatz  K, Peter  HH.  Common variable immunodeficiency: an update. Arthritis Res Ther. 2012;14(5):223.
PubMed   |  Link to Article
Batchelor  JM, Todd  PM.  Treatment of ulcerated necrobiosis lipoidica with intravenous immunoglobulin and methylprednisolone. J Drugs Dermatol. 2012;11(2):256-259.
PubMed
Quimby  SR, Muller  SA, Schroeter  AL.  The cutaneous immunopathology of necrobiosis lipoidica diabeticorum. Arch Dermatol. 1988;124(9):1364-1371.
PubMed   |  Link to Article
Laukkanen  A, Fräki  JE, Väätäinen  N, Korhonen  T, Naukkarinen  A.  Necrobiosis lipoidica: clinical and immunofluorescent study. Dermatologica. 1986;172(2):89-92.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.
Clinical Images of Affected Areas Before Treatment

Lower pretibial right (A) and left (B) legs before intravenous immunoglobulin therapy showing large and ulcerative plaques of necrobiosis lipoidica.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Clinical Image of Affected Areas After Treatment

Lower pretibial aspect of the legs after Intravenous Immunoglobulin therapy showing substantial healing.

Graphic Jump Location

Tables

References

Ngo  B, Wigington  G, Hayes  K,  et al.  Skin blood flow in necrobiosis lipoidica diabeticorum. Int J Dermatol. 2008;47(4):354-358.
PubMed   |  Link to Article
Salzer  U, Warnatz  K, Peter  HH.  Common variable immunodeficiency: an update. Arthritis Res Ther. 2012;14(5):223.
PubMed   |  Link to Article
Batchelor  JM, Todd  PM.  Treatment of ulcerated necrobiosis lipoidica with intravenous immunoglobulin and methylprednisolone. J Drugs Dermatol. 2012;11(2):256-259.
PubMed
Quimby  SR, Muller  SA, Schroeter  AL.  The cutaneous immunopathology of necrobiosis lipoidica diabeticorum. Arch Dermatol. 1988;124(9):1364-1371.
PubMed   |  Link to Article
Laukkanen  A, Fräki  JE, Väätäinen  N, Korhonen  T, Naukkarinen  A.  Necrobiosis lipoidica: clinical and immunofluorescent study. Dermatologica. 1986;172(2):89-92.
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles